BI-1910 as a Single Agent and in Combination With Pembrolizumab for the Treatment of Advanced Solid Tumors
Conditions: Solid Tumors; Non Small Cell Lung Cancer; Hepatocellular Carcinoma Interventions: Drug: BI-1910; Drug: Pembrolizumab Sponsors: BioInvent International AB Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Carcinoma | Hepatocellular Carcinoma | Liver Cancer | Lung Cancer | Non-Small Cell Lung Cancer | Research